Skin News

Wednesday, August 06, 2008 NeoStrata Reports Novel Nonprescription Coal Tar Solution Provides Significant Benefits Versus Calcipotriol for Moderate Psoriasis
Findings from an ongoing 12-week study demonstrate benefits of a novel, nonprescription topically applied LCD (coal tar) solution (Psorent™) versus calcipotriol cream (Dovonex^®) in treatment of moderate plaque psoriasis...

Tuesday, August 05, 2008 Proposed Bill Would Finalize Sunscreen Labeling Rules
Two US Senators have introduced a bill designed to compel the FDA to make a set of proposed rules on sunscreen labeling final…

Monday, August 04, 2008 Manhattan Pharmaceuticals Reports Phase IIa Results of PTH (1-34) for Psoriasis; Cream is Well Tolerated but No Significant Improvement in Treated Lesions Compared With Vehicle
Data from from the phase IIa clinical study of a reformulated topical PTH (1-34) for the treatment of psoriasis did not demonstrate a statistically significant improvement in the overall disease severity of treatment lesions or signs and symptoms of psoriasis compared with vehicle gel...

Wednesday, July 30, 2008 As Doctors Cater to Looks, Skin Patients Wait
Dermatology is becoming a two-tier business in which cosmetic patients, who are generally seeking more expensive procedures, are given preferential treatment to medical patients…

Wednesday, July 23, 2008 Sunscreen Safety Is Called Into Question
After an environmental group questioned the safety of many popular sunscreen brands, consumers are left questioning which, if any, type of sunscreen they should use…

Tuesday, July 22, 2008 Varicose, Spider Veins May Be Inevitable for Some
Although some perceive spider and varicose veins as a cosmetic concern, the condition can lead to serious health problems and may require surgical intervention…

Thursday, July 17, 2008 Classification and Categorization of Psoriatic Arthritis
Researchers in the field of psoriatic arthritis are working to overhaul Moll and Wright’s criteria for the classification and categorization of the disease…

Tuesday, July 15, 2008 Wyeth Reports European Commission Announces Marketing Authorization for 50 mg Once-Weekly Enbrel^® (etanercept) for Patients With Moderate-to-Severe Psoriasis
The European Commission announced a new 50 mg Enbrel^® (etanercept) once-weekly dosage regimen as an alternative to the currently approved 25 mg Enbrel twice-weekly regimen for the treatment of moderate-to-severe plaque psoriasis...

Monday, July 14, 2008 Welichem's Phase I Clinical Trial of Topical WBI-1001 Meets Primary, Secondary Objectives in Psoriasis
Welichem Biotech, a biotechnology company developing therapeutic drugs in the fields of autoimmune, inflammatory diseases, and cancer, announced positive results from a phase I clinical trialevaluating topically applied WBI-1001 in psoriasis patients...

Thursday, July 10, 2008 Cancer Drug Velcade^® Looks Promising for Lupus Nephritis
Bortezomib, which prolonged survival and prevented nephritis in mice with lupus, looks set to move to human clinical trials...